Recursion Executive and Leadership Team

Najat Khan, the Chief Executive Officer, President & Member, Board of Directors at Recursion, directs the overarching strategic vision for the organization. Khan oversees the integration of machine learning and biological datasets to accelerate drug discovery pipelines. By aligning the Board of Directors with operational goals, the Chief Executive Officer ensures the company maintains a competitive edge in the biotechnology sector. This leadership role involves navigating complex regulatory landscapes while scaling the Recursion Operating System across international markets. Najat Khan drives the mission to industrialize biological research, ensuring that technological innovations translate into tangible patient benefits. Through rigorous oversight of the Recursion Map, the President maintains focus on unconstrained biological exploration. Ultimately, the Chief Executive Officer secures the long-term viability of the company by fostering a culture of scientific excellence and operational efficiency, positioning the firm as a leader in modern drug development.

Madeleine Lyman, the Executive Business Partner To Ben Taylor. Chief Financial Officer and Sid Jain at Recursion, manages critical financial workflows and executive alignment. Lyman coordinates resource allocation across the finance and business development departments to support the scaling of the Recursion Operating System. By facilitating communication between the Chief Financial Officer and key leadership, the Executive Business Partner ensures fiscal discipline during rapid expansion. This role involves analyzing complex datasets to inform investment decisions in chemical and biological research. Madeleine Lyman optimizes internal processes to streamline the interaction between financial planning and scientific output. Overseeing the operational synchronization of the executive suite, the Executive Business Partner maintains focus on long-term growth targets. Through meticulous management of cross-functional initiatives, Lyman supports the company's mission to decode biology. This position directly impacts the financial health of the organization by ensuring that capital deployment aligns with the strategic goals of the Recursion Map.

Vicki Goodman, the Chief Medical Officer at Recursion, directs the clinical development strategy for the company's proprietary drug discovery pipeline. Goodman oversees the translation of biological insights derived from the Recursion Map into actionable clinical trials. By managing relationships with regulatory bodies and clinical research organizations, the Chief Medical Officer ensures that all therapeutic candidates meet rigorous safety and efficacy standards. This leadership role involves guiding the medical team through the complexities of drug development, from early-stage research to late-stage clinical validation. Vicki Goodman integrates medical expertise with machine learning outputs to refine the company's approach to foundational biology. Overseeing North American and global clinical initiatives, the Chief Medical Officer maintains a focus on improving patient lives through innovative biotechnology. Through strategic oversight of clinical programs, Goodman ensures that the company's technological advancements effectively address unmet medical needs, ultimately driving the success of the entire drug discovery portfolio.

Ryan Kelly, the Chief Communications Officer & Leadership Executive & Team Member at Recursion, architects the corporate narrative and stakeholder engagement strategy. Kelly oversees the dissemination of information regarding the Recursion Operating System and the company's advancements in machine learning-driven drug discovery. By managing public relations and internal communications, the Chief Communications Officer ensures alignment between the company's mission and external market perception. This leadership role involves coordinating with the executive team to articulate the value of the Recursion Map to investors, partners, and the broader scientific community. Ryan Kelly drives initiatives that highlight the company's role in industrializing biology, ensuring that the brand remains synonymous with innovation. Overseeing global communication efforts, the Chief Communications Officer maintains a consistent message across all operational regions. Through strategic storytelling and stakeholder management, Kelly supports the company's growth objectives, ensuring that the organization's impact on drug discovery remains clear and compelling to all relevant audiences.